Targeting of vasculature in cancer and other angiogenic diseases [3]

Trends in Immunology

Volumn 22, Issue 3, 2001, Pages 129-

  Kumar, Shant ^a   Li, Chenggang ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ENDOGLIN; INTEGRIN; THALIDOMIDE; VASCULOTROPIN;

ANGIOGENESIS; CANCER CELL; DRUG RESISTANCE; HUMAN; LETTER; NONHUMAN; RHEUMATOID ARTHRITIS; TUMOR GROWTH; VASCULAR DISEASE;

EID: 0034912850     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(00)01840-8     Document Type: Letter

References (14)

1. Clinical trials of antibody therapy
2. Antibody targeting of tumour vascular endothelial cells
3. Fighting cancer by attacking its blood supply
4. Tumour angiogenesis: Therapeutic implications
5. Thalidomide for Crohn's disease
6. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin
7. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
8. The endothelium as a target for gene therapy; tumours, cardiovascular disease and neurodegenerative disorders
9. Angiogenesis in breast cancer: The role of transforming growth factor β and CD105
10. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin
11. Induction of lasting complete regression of preformed distinct solid tumours by targeting the tumour vasculature using two new anti-endoglin monoclonal antibodies
12. Antiangiogenic radioimmunotherapy of human solid tumours in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies
13. Imaging of tumour vasculature by targeting the TGFβ binding receptor endoglin
14. New discoveries still abundant in monoclonal antibody research